This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
IRVINE, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference in New York, NY.
Event: Jefferies 2014 Global Healthcare Conference
Date: Wednesday, June 4, 2014
Time: 11:00 a.m. ET / 8:00 a.m. PT
An audio webcast of the presentation will be available by visiting the investor relations section of Endologix's website at
www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at
CONTACT: COMPANY CONTACT:
John McDermott, CEO
Shelley Thunen, CFO
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020